Mosel Pearlman-Ramirez v. HHS - Tdap, Guillain-Barré Syndrome (GBS) (2023)
Case summary [AI summaries can sometimes make mistakes]
Mosel Pearlman-Ramirez filed a petition for compensation on June 9, 2022, alleging that the Tdap vaccine received on April 19, 2021, caused Guillain-Barré Syndrome (GBS) and residual effects lasting more than six months. The respondent, the Secretary of Health and Human Services, denied that the vaccine caused the alleged injury.
Despite this denial, the parties reached a stipulation for award, agreeing that Mosel Pearlman-Ramirez should receive compensation. The court adopted the stipulation, awarding a lump sum of $110,000.00 to cover all damages.
This decision was entered on May 23, 2023, following the parties' agreement to expedite judgment. The public decision does not describe the onset of symptoms, specific clinical details, diagnostic tests, treatments, or expert witnesses.
Petitioner counsel was Elizabeth Abramson of Maglio Christopher & Toale, P.A., and respondent counsel was Voris Johnson of the United States Department of Justice. Special Master Herbrina Sanders issued the decision.
Theory of causation
Petitioner Mosel Pearlman-Ramirez alleged that the Tdap vaccine administered on April 19, 2021, caused Guillain-Barré Syndrome (GBS) and residual effects lasting over six months. The respondent denied causation. The parties entered into a stipulation for award, agreeing to a lump sum of $110,000.00 to compensate for all damages. The public decision does not detail the specific theory of causation, medical experts, or the mechanism by which the vaccine allegedly caused the GBS. The decision was issued by Special Master Herbrina Sanders on May 23, 2023, with Petitioner represented by Elizabeth Abramson and Respondent by Voris Johnson.
Source PDFs
USCOURTS-cofc-1_22-vv-00640